![Jason Slingsby](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jason Slingsby
Nessuna posizione attualmente
Profilo
Jason Slingsby is the founder of ProtAffin Biotechnologie AG, which was founded in 2005.
He held the title of Chief Executive Officer at ProtAffin Biotechnologie AG.
Dr. Slingsby's former jobs include Chief Business Officer at Oxford Biomedica Plc from 2018 to 2023, Principal at InterCel, Inc., Principal at Sosei Co. Ltd., and Member-Supervisory Board at Zytoprotec GmbH.
Dr. Slingsby's education includes a doctorate from Imperial College London and an MBA from London Business School.
Precedenti posizioni note di Jason Slingsby
Società | Posizione | Fine |
---|---|---|
OXFORD BIOMEDICA PLC | Corporate Officer/Principal | 01/05/2023 |
Zytoprotec GmbH
![]() Zytoprotec GmbH Pharmaceuticals: MajorHealth Technology Zytoprotec GmbH develops and manufactures drugs for peritoneal dialysis. It specializes in the research and development of its pipeline, which encompasses PD-protec, a patented-protected solution and ICO-protec, a cytoprotective PD solution to address the market for non-glucose based PD solutions. The firm focus areas encompass portfolio management, therapeutic approach, patent management and research services. The company was founded by Karl Altenhuber, Christoph Aufricht and Christian Hoenig in 2007 and is headquartered in Vienna, Austria. | Direttore/Membro del Consiglio | - |
Sosei Co. Ltd.
![]() Sosei Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sosei Group Corp., Sosei Co. Ltd. is a world-leader in GPCR medicine design and development. The company is based in Tokyo, Japan. The Japanese company obtains and maintains intellectual property rights to protect its innovations and technologies. | Corporate Officer/Principal | - |
InterCel, Inc. | Corporate Officer/Principal | - |
ProtAffin Biotechnologie AG
![]() ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Amministratore Delegato | - |
Formazione di Jason Slingsby
Imperial College London | Doctorate Degree |
London Business School | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
OXFORD BIOMEDICA PLC | Health Technology |
Aziende private | 4 |
---|---|
ProtAffin Biotechnologie AG
![]() ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Health Technology |
Sosei Co. Ltd.
![]() Sosei Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sosei Group Corp., Sosei Co. Ltd. is a world-leader in GPCR medicine design and development. The company is based in Tokyo, Japan. The Japanese company obtains and maintains intellectual property rights to protect its innovations and technologies. | Commercial Services |
InterCel, Inc. | Communications |
Zytoprotec GmbH
![]() Zytoprotec GmbH Pharmaceuticals: MajorHealth Technology Zytoprotec GmbH develops and manufactures drugs for peritoneal dialysis. It specializes in the research and development of its pipeline, which encompasses PD-protec, a patented-protected solution and ICO-protec, a cytoprotective PD solution to address the market for non-glucose based PD solutions. The firm focus areas encompass portfolio management, therapeutic approach, patent management and research services. The company was founded by Karl Altenhuber, Christoph Aufricht and Christian Hoenig in 2007 and is headquartered in Vienna, Austria. | Health Technology |
- Borsa valori
- Insiders
- Jason Slingsby